IFITM10 增强瘤血管生成,并通过STAT3激活促进癌症进展
Youjian Li1, Mengjie Wang2, Xun Li3
1College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts and Sciences, 402160 Chongqing, China.
Frontiers in bioscience (Landmark edition)
|August 29, 2024
概括
干扰素诱导的跨膜蛋白10 (IFITM10) 通过通过STAT3激活增强血管生成,促进结直肠癌 (CRC) 的生长. IFITM10可以作为CRC的预后生物标志物和治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 大肠直肠癌 (CRC) 具有快速进展和转移的特点.
- 干白素-6/STAT3信号过活化在CRC促进血管新生,促进营养的获取.
- 了解驱动CRC进展的分子机制对于开发有效疗法至关重要.
研究的目的:
- 调查干扰素-γ诱导蛋白10 (IFITM10) 在结直肠癌中的作用.
- 确定IFITM10表达和CRC患者的临床结果之间的相关性.
- 阐明IFITM10影响CRC中的血管生成和STAT3激活的机制.
主要方法:
- 对IFITM10表达和临床结果相关性的癌症基因组图谱数据库的分析.
- 使用细胞计数工具-8和管形成试验评估细胞血管生成能力.
- 通过免疫光,西斑和ELISA检测评估潜在的机制.
主要成果:
- IFITM10在结直肠癌中被上调,并且与瘤血管生成有积极的相关性.
- 抑制IFITM10降低了STAT3酸化,表明IFITM10介导的血管生成依赖于STAT3激活.
- IFITM10表达水平与患者的预后有关,这表明其作为生物标志物的潜力.
结论:
- 在结直肠癌进展期间,IFITM10通过STAT3激活增强血管生成.
- IFITM10代表着结直肠癌的潜在治疗标.
- 向IFITM10可能通过抑制瘤血管生成来提供一种新的CRC管理策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Intracellular Signaling Affects Focal Adhesions
2.6K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.6K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493


